T.TO -0.04ENB.TO 0.39BEP.UN.TO -1.15CP.TO -0.75VRT -19.67NVDA 2.52TSM -0.79JPM -1.03
Moderna (MRNA)

NASDAQ:MRNA

Moderna (MRNA)

146.69
+2.72 (1.89%)
as of Sep 14, 2026, 8:00:00 pm Market Open.
146 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconSep 14, 2026, 12:00 am

This summary was created by AI, based on 6 opinions in the last 12 months.

Moderna (MRNA-Q) has recently garnered significant attention on the stock market, experiencing a remarkable surge in share prices following notable medical advancements, particularly in oncology. As of now, the stock is trading around $140.13, reflecting an impressive increase of over 154% from the start of the month. Despite being one of the top performers in various months, experts highlight that the company is still operating at a loss, with profitability not anticipated until 2029. Investor excitement is further fueled by ongoing clinical trials for innovative drugs, including personalized anti-cancer vaccines. However, some experts suggest that while the stock has performed well, potential investors should consider waiting for a pullback before entering the market.

consensus icon
Consensus
Bullish
valuation icon
Valuation
Overvalued
review icon
Similar
PFE
PARTIAL BUY

Moderna(MRNA)

Mar 17, 2023

Likes it long term. They will reveal data on a personalized cancer vaccine coming up. But short term it's volatile, anybody's guess.

Photo of Stephen Weiss, Founder, Short Hills Capital PartnersStephen Weiss, Founder, Short Hills Capital Partners
Owned
Unlock Rating
N/A

Stock price when the opinion was issued

$146.69

As of Sep 14, 2026. Market Open.

Pharma & Healthcare
RISKY

Moderna(MRNA)

Dec 14, 2022
They just had a breakthrough with a cancer drug they had long been developing. With that, Moderna doesn't need the potential Covid-vaccine business with China (if that happens there). After a 40-point rally, it is a little speculative.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$213.96

Stock price when the opinion was issued

$146.69

As of Sep 14, 2026. Market Open.

Pharma & Healthcare
BUY

Moderna(MRNA)

Oct 28, 2022
They report next week. Not sure how it'll pay out because of the slower uptake of their 4th booster shot, but they have an incredible pipeline.
Photo of Stephen Weiss, Founder, Short Hills Capital PartnersStephen Weiss, Founder, Short Hills Capital Partners
Owned
Unlock Rating
$146.55

Stock price when the opinion was issued

$146.69

As of Sep 14, 2026. Market Open.

Pharma & Healthcare
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Moderna(MRNA)

Sep 29, 2022
(A Top Pick Jul 07/22, Down 30.4%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRNA has triggered its stop at $120. To remain disciplined, we recommend covering the position at this time.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$118.19

Stock price when the opinion was issued

$146.69

As of Sep 14, 2026. Market Open.

Pharma & Healthcare
COMMENT

Moderna(MRNA)

Sep 21, 2022
It has suffered enough. A well-run company, but shares can fall lower. Enough is enough.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$125.76

Stock price when the opinion was issued

$146.69

As of Sep 14, 2026. Market Open.

Pharma & Healthcare
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Moderna(MRNA)

Jul 07, 2022
Stockchase Research Editor: Michael O'Reilly Trading at only 5x earnings, this is one of the least expensive stocks in the S&P500. The company is looking to expand its COVID vaccine in Europe and the US for children under 6 years. Recently reported earnings smashed analyst expectations by over 65% and is generating a ROE over 120%. The company has been prudently using a small portion of cash reserves to help aggressively buy back shares and retire debt. We recommend a stop loss at $120, looking to achieve $228 -- upside potential over 42%. Yield 0% (Analysts’ price target is $228.00)
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)Unlock Rating
$172.34

Stock price when the opinion was issued

$146.69

As of Sep 14, 2026. Market Open.

Pharma & Healthcare
BUY

Moderna(MRNA)

May 13, 2022
Biotechs have strong balance sheets, better than a few years ago. Likes this as well as Amgen. Better to buy individual biotech stocks over ETFs.
Photo of Pete NajarianPete NajarianUnlock Rating
$137.85

Stock price when the opinion was issued

$146.69

As of Sep 14, 2026. Market Open.

Pharma & Healthcare
BUY

Moderna(MRNA)

May 13, 2022
Has lightened his holding (and all his stocks) because of this market, but it remains one of the cheapest stocks out there with a lot of cash in order to buy another company. Their drug pipeline continues to grow. It's the best biotech out there.
Photo of Stephen Weiss, Founder, Short Hills Capital PartnersStephen Weiss, Founder, Short Hills Capital Partners
Owned
Unlock Rating
$137.91

Stock price when the opinion was issued

$146.69

As of Sep 14, 2026. Market Open.

Pharma & Healthcare
DON'T BUY

Moderna(MRNA)

May 12, 2022
Chart has come full circle. Covid vaccine was a tremendous short-term win for the company and society. Revenues are trailing off for the next 2 years. Avoid the rockets and torpedoes. Look at PFE instead.
Photo of Paul MacDonaldPaul MacDonald
No
Unlock Rating
$129.26

Stock price when the opinion was issued

$146.69

As of Sep 14, 2026. Market Open.

Pharma & Healthcare
COMMENT

Moderna(MRNA)

Apr 29, 2022
They report Wednesday. They made a lot of cash during the pandemic, but they need to expand and can't be a one-trick pony. Need to broaden their portfolio.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$134.41

Stock price when the opinion was issued

$146.69

As of Sep 14, 2026. Market Open.

Pharma & Healthcare
BUY ON WEAKNESS

Moderna(MRNA)

Feb 14, 2022
Shares are plunging today. They sold over $18 billion of vaccines for 2022. All vaccine stocks have fallen for the same reason: Covid is ending. He's short calls and long puts for Moderna (has been so for many months). Post-vaccine world, he thinks this will be the most-valuable healthcare company, because they have a platform that's grown from 21 therapeutics and vaccines to over 40 in the span of a year. The future is extremely bright. But biotech stocks are event-driven. So, no events, then shorting happens and sellers get impatient.
Photo of Stephen Weiss, Founder, Short Hills Capital PartnersStephen Weiss, Founder, Short Hills Capital Partners
Owned
Unlock Rating
$140.01

Stock price when the opinion was issued

$146.69

As of Sep 14, 2026. Market Open.

Pharma & Healthcare
WATCH

Moderna(MRNA)

Jan 24, 2022
It made a ton of money since Covid, but it hasn't done much with that cash and didn't develop a pill treatment like Pfizer. He wishes they would buy weaker biotechs with that cash to grow. He expects/hope that.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
No
Unlock Rating
$157.27

Stock price when the opinion was issued

$146.69

As of Sep 14, 2026. Market Open.

Pharma & Healthcare
DON'T BUY

Moderna(MRNA)

Jan 04, 2022
Fallen a lot recently. If we believe that Covid becomes endemic and we don't all need shots, what's going to happen to MRNA? Crazy cheap at 8-9x next year's earnings, beautiful balance sheet, technology works, but what's the next catalyst? He tends to stay away from biotechs and pharmas, as the science is too hard to understand.
Photo of Barry SchwartzBarry Schwartz
No
Unlock Rating
$228.98

Stock price when the opinion was issued

$146.69

As of Sep 14, 2026. Market Open.

Pharma & Healthcare
COMMENT

Moderna(MRNA)

Jan 03, 2022
Among the 10 top performers on the S&P of 2021 #3, up 143%. He doubts MRNA can repeat this increase unless everybody gets a fourth dose of their vaccine or can diversify into, say, cancer vaccines. He loves management, but the stock isn't pricing in the chance the Omicron will come and go quickly (and result in a bad kind of herd immunity).
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
No
Unlock Rating
$235.05

Stock price when the opinion was issued

$146.69

As of Sep 14, 2026. Market Open.

Pharma & Healthcare
Showing 31 to 45 of 67 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

TPZ.TO -0.04$12.69
KBL.TO 0.98$42.9
PPL.TO 0.315$65.7
AQN.TO -0.08$7.38
EMA.TO -0.63$67.54

Today's Top Picks

T.TO -0.04$12.69
ENB.TO 0.39$67.42
BEP.UN.T… -1.15$40.98
CP.TO -0.75$124.24
VRT -19.67$237.39

Popular Articles

Latest Sell Signals

CPX.TO -0.75$124.24
AVGO -0.01$344.71
APP -0.93$333.31
XRE.TO 0.05$15.73
ORCL -3.95$140.84

Most Recent Experts

Ryan Bushell

Ryan Bushell

Newhaven Asset Management

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically

You may also like